Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH
NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
This is another feather in Frank’s cap.
80 million in cash now.
Enjoy the weekend!
$PDSB
The International Liver Congress 2021 will begin on
Wednesday June 23 and ends on Saturday, June 26 2021
https://easl.eu/event/the-international-liver-congress-2021/?gclid=EAIaIQobChMI787Qkvij8QIVdAnnCh0pXwfZEAAYAiAAEgJPRPD_BwE
NASH is 35 Billion dollar market that will near 100 Billion next 5-10 years.
Phase 2A data on CRV431 225mg between next week and the end of June. Last year they announced the day before the conference they where presenting. And as well as inclusion into Russell index!!
Phase CRV431 2A preliminary conclusions:
1.Reduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjects.
2.CRV431 in NASH Phase 2a Preliminary ConclusionsReduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjectsCRV431 concentration predicts reductions in serum alanine transaminase.
3.Trial Simulations suggest greater expected efficacy at 150 mg and 225 mg dose levels.
4.Bioinformatics with AI-POWR?reveal significant interactions with collagen regulating genes.
5.Confirmation of these effects will be fully evaluated using the 225 mg cohort and the final genomic, lipidomic, and biomarker data for a full simulation of the Phase 2b Trial.
AI-POWR™ Confers Strategic Advantages from Clinical Trials to Commercialization:
A.Novel drug target selection
B.Biomarker selection and validation
C.Patient selection (-responder analysis)
De-risk clinical trials
D.Improve drug development efficiency with cost savings
HEPA molecule CRV431 for NASH is safer than MDGL & AKRO & HEPA Efficacy looks next level. These 2 companies MDGL & AKRO are both Billion dollar plus companies look for HEPA market cap to grow exponentially.
Key take away: In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
MNMD is Poetry in motion.
$MNMD
Added a few more to my stash just now thanks for the cheapies.
Coiled tight and ready to go.
$HEPA
Just another day at the office. Banking hard!
Operation Green Stakes.
Stock pickers market.
$PDSB
The next chapter new CEO and Nasdaq listed let’s go!
$MNMD
Doubled down at 12.85
Shorts are going to get pulverized!
$BB
Nice looking good!
$SPCE
HEPA This will squeeze soon. Accumulating for a breakout next!
ALWAYS EARLY.
HEPA is a gapper in the making will go on a tear soon!
THINK BIG.
The chasers will come soon. Book it.
Bios are heating up!
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
$HEPA
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
It’s go time again!
Destroy little Shorty & all circus clowns.
https://tenor.com/view/hello-bear-waving-friendly-bear-grizzly-bears-waving-gif-8647530
$PDSB
Keep in mind that HEPA CRV431 is far and away the best anti-fibrotic in the clinic today. Nothing else compares.
HEPA CRV431
If you have what it takes to hold your shares tightly, Hepion is gonna make you a mountain of cash...
It can double or triple in a blink of an eye with the catalysts it has on tap.
Keep in mind that HEPA CRV431 is far and away the best anti-fibrotic in the clinic today. Nothing else compares..
Started buying PDSB in the 2.00 range and sold half my shares between 12.00-13.25. PDSB moved huge to the upside on volatile days in the market when most stocks where down HEPA a 500%-1000% move is coming in the next 12-18 months These small cap biotech can move on a dime. No matter what the markets are doing Don't get robbed of your shares you hold like a real man for a year or two your tax rate drops tremendously.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
Great stock trader looks great! Solid work on the board thank you!
$HEPA
Setting up for a parabolic move from these levels.
Lock & Loaded with plenty of ammo to add to my stash.
Blue skies & greener pastures ahead.
HEPA down 8% for the year. I see 500%-1000% upside with in the next 12-18 months or sooner.
Always early!
I see the angles before they are played..
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
$HEPA
Thank you!
Adding heavy at these levels.
Red to green move and we take off!
$HEPA
Sensational!
HEPA
It's all smoke & mirrors. A few retail scaredy cats on low volume got robbed for their shares while the smart money is adding hand over fist..
This is the last time you'll see these levels.
Looks like tomorrow is 2.20s, Friday 2.40s, and next week.... KABOOM!
$HEPA
Drug companies and liver organizations have signaled that NASH medicines represent a $35 billion market opportunity.
Key take away: In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
Objectives: Safety and tolerability of once daily (qd) 75 mg and 225 mg doses of CRV431 in presumed NASH fibrosis stage 2 (F2)/fibrosis stage 3 (F3) patients compared to placebo control for 28 days?Exploratory biomarkers of fibrosis and lipid metabolism: collagens, matrix metalloproteinases, lipidomics, and genomics?Multi-omic/trait data analysis by AI-POWR?
Study Design: Multi-center (10 Sites), single-blind, placebo-controlled study?Univariate Endpoints: AST, Pro-C3, ELF Score, Fibroscan.
AI-POWR™ Confers Strategic Advantages from Clinical Trials to Commercialization
Hepion is focused first on utilizing AI-POWR™ in its Phase 2a clinical program evaluating CRV431 in non-alcoholic steatohepatitis (NASH). NASH is a highly heterogenous disease underpinned by complex biochemical and pathological processes. AI-POWR™ has the potential to facilitate a precision medicine-based approach to treating NASH through its ability to identify CRV431 responders and inform the development of biomarkers. AI-POWR™ can be used to fine-tune patient selection for clinical trials or when designing clinical studies. In addition, AI-POWR™ can be used to to identify and evaluate additional potential indications for CRV431 to expand our footprint in the cyclophilin inhibition therapeutic space and beyond.
Novel drug target selection.
Biomarker selection and validation.
Patient selection (-responder analysis.)
De-risk clinical trials.
Improve drug development efficiency with cost savings.
HEPA tackling Chronic Liver Disease - CRV431 Mechanism of Action.
Solid accumulation ahead of the breakout.
Adding with both hands!!
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
$HEPA
HEPA x7 current market cap of 167 million puts the valuation at right under 1.2 Billion.
Key take away: In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish! 1.2 Billion valuation puts the HEPA market cap in line with it's peers. HEPA has CRV431 is very safe with top line data. Lots of upside from the current levels.
HEPA Lots of catalysts & hammers the company is about to drop!
Savvy biotech investors accumulating HEPA shares from the impatient & uneducated retail investors. Lock your shares up!!
2 upgrades to $4.50 and $14.00 more to come IMO which by 5 year chart has in April of 2020 was over $16.00 a share.
June 2021 HEPA Biz Presentation.
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash.
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash.
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash.
$HEPA
Copy that Frank is a smart cookie!
$PDSB
welcome Robert Barrow our new CEO.
$mnmd
Primed to gap up hard!
Showing high relative strength.
Adding huge ahead of the next breakout.
Key take away: In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA website
https://hepionpharma.com
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
$HEPA
Added huge this am! HEPA is now My favorite small cap bio has the most upside to transform into a mid cap and then blue chip with a potential blockbuster for NASH. What else do you want a company that has that kind of potential at 160 million market cap 120 million in cash burning less than 5 million a quarter with an experienced management team that has the potential to be a company that becomes worth tens of billions. Hold your shares tight to the vest lock them up in the safe. If you sold your shares call the police you have been robbed. They will not come and save you. They have been defunded! Long and strong! This stock will quantum leap from these levels.
$HEPA
Fact: The inflows have been massive the last 2 weeks. Reason why In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
Lots of catalysts & hammers the company has in its arsenal.
Bottom line The FDA looks for safety first we have the safest NASH drug our efficacy data is better than MDGL & AKRO. there market caps our almost 10x HEPA. Smart savvy biotech investors with deep pockets know this and are accumulating all they can of HEPA at these levels.
One morning we can wake up and see the price has tripled from its 160 market cap. Also they have 120 million in cash burning under 5 million a quarter. Lots of moving parts here. Gilead & Novo in the mix we will see? A new molecule being added to the pipeline. This management team is experienced 100 years total and world renown experts on cyclophilin inhibitors. They brought a FDA approved blockbuster drug to market already.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Gaining strength!
Bullish Pattern Detected.
Setting up for a big run!!!
Extremely Undervalued compared to its peers who have inferior safety & efficacy data for Nash.
$13.00 gives HEPA a billion dollar valuation.
Those who don't know the most basic stuff, like the difference between authorized shares and issued shares, really shouldn't be trading stocks at all, but then they won't be around for very long.
HEPA 160 Million market cap. 120 Million in cash burning under 5 million a quarter.
Remember In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action:
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 170 Million market cap 120 million in cash (well funded)
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
$HEPA
PDS Biotech Announces Proposed Offering of Common Stock
FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by PDS Biotech. PDS Biotech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering.
PDS Biotech intends to use a portion of the net proceeds from this offering for the development of our clinical pipeline and for general corporate purposes including working capital.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and became effective on July 31, 2020. A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, NY 10022, Attn: Capital Markets Department, or by email at prospectus@cantor.com.
$PDSB
Release the kraken Franky baby!
Destroy Shortie!
PDSB JUNE 2021 Biz Presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/june/PDSB_Corporate_Overview_-_June_7_FINAL_1.pdf
PDSB website.
https://www.pdsbiotech.com/
52 week low 1.12
52 week high 13.48
https://giphy.com/gifs/animation-kraken-soDqW21ZbC1oc
$PDSB
This stock is setting up for a parabolic move.
Don't get robbed for your shares!
HEPA 10X potential from these levels & longer term possible 100x ROI from these levels!
Hepa I believe new multi millionaires will be created here. Just like PDSB my other pick when it was trading in the 2.00
They ran this same scheme on PDSB, and with a lot of the same variables to work with, like the back-to-back offerings. The goons took PDSB down to .61 last spring, and now they've got a twenty-bagger.
A twenty-bagger with HEPA is 29.00...
$HEPA
Grand loading zone!
HEPA has one of the best setups out there !!! What a beauty..
This was just published today, and I just know this is why Foster HEPA CEO talked about the blood-brain barrier in that recent SA interview.
They used Debio-025, but CRV431 is the most potent cyclophilin inhibitor known, by a wide margin, &
USC study reveals potential new treatment target for Alzheimer's disease.
https://www.eurekalert.org/pub_releases/2021-06/ksom-usr061121.php
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
(CRV431 is the most potent cyclophilin inhibitor known, by a wide margin)
Scooped up a few more today!
$MNMD
Nice price action!
$SPCE
This tiger is napping will wake up soon.
$PDSB
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Got filled!
These clowns MM are are about to get lit up lots of chatter in massive discord’s about spanking Sabbys Fat Hal this is going to be fun! Power to the people!
HEPA has more up side Return on investment than any other bio under 170 million market cap!!
HEPA Billion plus market cap in the making! Don’t sleep on it!!
Safer and top line data better than MDGL
MDGL 1.8 Billion market cap
HEPA 170 million market cap
$HEPA
Adding heavy to my stash at the open. HEPA has multi billion market cap potential hard to find in a bio under 200 million market cap. I see the angles before there being played.
HEPA just the beginning!!
Chronic Liver Disease - HEPA's CRV431 Mechanism of Action:
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Most undervalued Biotech stock on planet earth! Book it!
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
Tackling Chronic Liver Disease - CRV431 Mechanism of Action